Holen Sie sich die Stockscreener-App
14.81
4.08%
-0.63
Handel nachbörslich:
14.81
Schlusskurs vom Vortag:
$15.44
Offen:
$15.62
24-Stunden-Volumen:
1.72M
Relative Volume:
1.98
Marktkapitalisierung:
$953.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-3.9873
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
-29.74%
1M Leistung:
-35.47%
6M Leistung:
+5.33%
1J Leistung:
+147.25%
1-Tages-Spanne:
$14.67
$15.62
1-Wochen-Bereich:
$14.67
$21.88
52-Wochen-Spanne:
$5.68
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.81 | 953.09M | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics - The Pharma Letter
CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at BTIG Research - MarketBeat
CGEM Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - sg.finance.yahoo.com
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Investing News Network
Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances By Investing.com - Investing.com Canada
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits
Cullinan Therapeutics (CGEM) Eyes Key Autoimmune and AML Data Re - GuruFocus
Cullinan delays early-stage data for arthritis drug (CGEX) - Seeking Alpha
Cullinan Therapeutics (CGEM) Shares Drop 7% as CLN-978 Data Rele - GuruFocus
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Yahoo Finance
Cullinan Therapeutics (CGEM) Sets Q4 2026 Clinical Updates Amid High Price-to-Sales Valuation - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 - GlobeNewswire
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Yahoo Finance
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - investingnews.com
Phase III results could broaden opportunity for Cullinan’s lead cancer drug - The Pharma Letter
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Should Phase 3 Lung Cancer Data Require Action From Cullinan Therapeutics (CGEM) Investors? - simplywall.st
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - Insider Monkey
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42 - Moomoo
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst CallSlideshow (NASDAQ:CGEM) 2026-09-14 - Seeking Alpha
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen - Investing.com South Africa
BTIG raises Cullinan Oncology stock price target on trial data - Investing.com
BTIG raises Cullinan Oncology stock price target on trial data By Investing.com - Investing.com Canada
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM) - Seeking Alpha
Stifel reiterates Cullinan Oncology stock Buy rating on trial data By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock Buy rating on trial data - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Yahoo Finance
CGEM: Zipalertinib plus chemotherapy achieved unprecedented PFS and CNS efficacy in first-line EGFR exon 20 NSCLC - TradingView
Cullinan Therapeutics stock falls despite positive trial data By Investing.com - Investing.com Canada
CGEM: Zipalertinib plus chemotherapy significantly improved PFS and ORR in EGFR ex20ins NSCLC - TradingView
Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3 - TradingView
Cullinan Therapeutics to Host Virtual Investor Event on Phase 3 REZILIENT3 Zipalertinib Data from IASLC WCLC 2026 - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Squarepoint Ops LLC Invests $3.06 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - Investing News Network
Cullinan Therapeutics (CGEM) Advances Lung Cancer Trial; Valuati - GuruFocus
Zipalertinib plus chemo shows survival benefit in lung cancer trial By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Sep 08 '26 |
Sale |
21.57 |
8,000 |
172,560 |
158,844 |
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):